XOMA Corporation (NASDAQ:XOMA)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, October 17th, MarketBeat.com reports. They presently have a $38.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 71.56% from the stock’s previous close.
Several other research analysts also recently commented on XOMA. ValuEngine raised shares of XOMA Corporation from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 12th. Zacks Investment Research raised shares of XOMA Corporation from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a report on Friday, July 14th. Finally, Wedbush reaffirmed a “hold” rating on shares of XOMA Corporation in a report on Monday, August 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $27.33.
Shares of XOMA Corporation (NASDAQ:XOMA) traded up 0.90% during midday trading on Tuesday, hitting $22.35. The stock had a trading volume of 50,883 shares. The company’s market cap is $169.82 million. XOMA Corporation has a 52 week low of $3.96 and a 52 week high of $24.92. The stock’s 50-day moving average price is $20.59 and its 200 day moving average price is $10.72.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/10/27/xoma-corporations-xoma-buy-rating-reaffirmed-at-hc-wainwright.html.
An institutional investor recently raised its position in XOMA Corporation stock. California Public Employees Retirement System increased its holdings in XOMA Corporation (NASDAQ:XOMA) by 95.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,780 shares of the biotechnology company’s stock after purchasing an additional 10,640 shares during the quarter. California Public Employees Retirement System owned 0.29% of XOMA Corporation worth $123,000 as of its most recent filing with the Securities & Exchange Commission. 32.92% of the stock is currently owned by institutional investors.
XOMA Corporation Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.